Johnson & Johnson (JNJD.XC)
| Previous close | 135.24 |
| Open | 134.22 |
| Bid | 0.00 x 0 |
| Ask | 134.82 x 0 |
| Day's range | 134.22 - 134.38 |
| 52-week range | 133.12 - 158.80 |
| Volume | |
| Avg. volume | 14 |
| Market cap | 323.41B |
| Beta (5Y monthly) | 0.53 |
| PE ratio (TTM) | 21.74 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 4.55 (3.36%) |
| Ex-dividend date | 20 May 2024 |
| 1y target est | N/A |
- Business Wire
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
NEW BRUNSWICK, N.J., June 04, 2024--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 17th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s execut
- Business Wire
Johnson & Johnson Completes Acquisition of Shockwave Medical
NEW BRUNSWICK, N.J., May 31, 2024--Johnson & Johnson (NYSE: JNJ) today announced it has completed its acquisition of Shockwave Medical. Shockwave is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson MedTech.
- PR Newswire
Sarepta Therapeutics Set to Join S&P MidCap 400
Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE: JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions.
